Shares of Guardant Health Inc. (GH) surged 6.48% in Thursday's trading session following the company's release of better-than-expected first-quarter 2025 financial results and an increase in its full-year revenue guidance.

The precision oncology company reported a narrower-than-anticipated loss for Q1, with adjusted earnings per share of $(0.49), significantly beating the analyst consensus estimate of $(0.81). Revenue for the quarter came in at $203.47 million, surpassing Wall Street expectations of $190.16 million and marking a robust 20.76% increase compared to the same period last year.

Guardant Health's strong performance was driven by growth across its business segments. Oncology revenue grew 20% to $150.6 million, while biopharma and data revenue increased 21% to $45.4 million. The company also reported progress in its screening business, with 9,000 Shield screening tests performed during the quarter.

In light of the strong Q1 results, Guardant Health raised its full-year 2025 revenue guidance to a range of $880 million to $890 million, representing growth of 19% to 20% compared to 2024. This updated outlook exceeded previous analyst expectations and likely contributed to the positive investor sentiment driving the stock's upward movement.